RT Journal Article
SR Electronic
T1 Polygenic Risk Score Improves the Accuracy of a Clinical Risk Score for Coronary Artery Disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.06.02.22275933
DO 10.1101/2022.06.02.22275933
A1 King, Austin
A1 Wu, Lang
A1 Deng, Hong-Wen
A1 Shen, Hui
A1 Wu, Chong
YR 2022
UL http://medrxiv.org/content/early/2022/06/03/2022.06.02.22275933.abstract
AB Background The value of polygenic risk scores (PRS) towards improving guideline-recommended clinical risk models for coronary artery disease (CAD) prediction is controversial. Here we examine whether an integrated polygenic risk score improves prediction of CAD beyond pooled cohort equations.Methods An observation study of 291,305 unrelated White British UK Biobank participants enrolled from 2006 to 2010 was conducted. A case-control sample of 9,499 prevalent CAD cases and an equal number of randomly selected controls was used for tuning and integrating of the polygenic risk scores. A separate cohort of 272,307 individuals (with follow-up to 2020) was used to examine the risk prediction performance of pooled cohort equations, integrated polygenic risk score, and PRS-enhanced pooled cohort equation for incident CAD cases. Performance of each model was analyzed by discrimination and risk reclassification using a 7.5% threshold.Results In the cohort of 272,307 individuals (mean age, 56.7 years) used to analyze predictive accuracy, there were 7,036 incident CAD cases over a 12-year follow-up period. Model discrimination was tested for integrated polygenic risk score, pooled cohort equation, and PRS-enhanced pooled cohort equation with reported C-statistics of 0.640 (95% CI, 0.634-0.646), 0.718 (95% CI, 0.713-0.723), and 0.753 (95% CI, 0.748-0.758), respectively. Risk reclassification for the addition of the integrated polygenic risk score to the pooled cohort equation at a 7.5% risk threshold resulted in a net reclassification improvement of 0.117 (95% CI, 0.102 to 0.129) for cases and -0.023 (95% CI, -0.025 to -0.022) for noncases [overall: 0.093 (95% CI, 0.08 to 0.104)]. For incident CAD cases, this represented 14.2% correctly reclassified to the higher-risk category and 2.6% incorrectly reclassified to the lower-risk category.Conclusions and Relevance Addition of the integrated polygenic risk score for CAD to the pooled cohort questions improves the predictive accuracy for incident CAD and clinical risk classification in the White British from the UK biobank. These findings suggest that an integrated polygenic risk score may enhance CAD risk prediction and screening in the White British population.Competing Interest StatementThe authors have declared no competing interest.Funding StatementChong Wu is partially supported by the National Institutes of Health (1R03AG070669). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for the UK Biobank study was obtained from the National Health Service National Research Ethics Service North West (11/NW/0382). The current research project (application number 48240) was approved by UK Biobank. Their ethical regulations cover the work of this study. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesUK Biobank data used in this study were available upon UK Biobank approval (https://www.ukbiobank.ac.uk, application number 48240). The summary statistics of genome-wide association studies (GWAS) of FinnGen Biobank can be obtained from https://www.finngen.fi/en/access_results upon registration, CARDIoGRAMplusC4D GWAS data can be directly downloaded at http://www.cardiogramplusc4d.org/data-downloads/, Japan Biobank GWAS data can be downloaded at https://humandbs.biosciencedbc.jp/en/hum0014-v22#42diseases. 1000 Genomes phase 3 reference panel can be obtained at https://www.internationalgenome.org/data-portal/data-collection/phase-3. The code can be downloaded from https://github.com/ChongWuLab/PolygenicRiskScore_CAD. https://www.finngen.fi/en/access_results http://www.cardiogramplusc4d.org/data-downloads/ https://humandbs.biosciencedbc.jp/en/hum0014-v22#42diseases https://www.internationalgenome.org/data-portal/data-collection/phase-3 https://github.com/ChongWuLab/PolygenicRiskScore_CAD (CVD)Cardiovascular disease;(PCE)pooled cohort equations;(CAD)coronary artery disease;(PRS)polygenic risk score;(GWAS)genome-wide association study;(AFR)African;(EAS)East Asian;(EUR)European;(SAS)South Asian;(HES)hospital episode statistics;(AUC)area under the curve;(NRI)net reclassification improvement;(IDI)integrated discrimination improvement;(CI)confidence interval